This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/9/2026
Good day and thank you for standing by. Welcome to the Village Farms International third quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising that your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker, Michael DeGiglio. Please go ahead.
Thank you, Tanya. And good morning, everyone, and thank you for joining us today. With me on the call are Hamid Shekarchi, our interim financial officer, Ann Gillin Lefever, our chief operating officer, and Sam Gibbons, senior vice president of corporate affairs and investor relations. I'll start this morning with a review of our Q3 highlights, then Hamid will cover the financials before our closing comments and analyst questions. Before we begin, though, I'd like to extend a warm welcome to Hamid on his first call with Village Farms. Hamid stepped into his new role after serving as CFO of a Canadian cannabis business and has 18 years of combined financial leadership and operational experience in cannabis. He knows our business inside and out, and we're excited to welcome him to our C-suite as Stephen Ruffini transitions to lead our M&A efforts. Now onto the quarter. We delivered record cannabis revenues of $55 million with approximately 43% of sales coming from some of the world's most attractive and fastest growing international markets. Consolidated net sales were $67 million, up 5% sequentially, Net income was $10 million or $0.08 per share. Adjusted EBITDA improved 18% sequentially to $18.2 million or 27% of sales. And we delivered operating cash flow of $9.5 million. Most importantly, we're achieving these results before benefiting materially from increased production capacity we have been converting in our Delta BC and Netherlands facilities, both of which position us for stronger revenue growth and profitability next year. As we noted in this morning's earnings release, the year-over-year variance in our Q3 gross margins was driven predominantly by a softer spot market for trim in the Canadian wholesale channel and not a reflection of us lowering international export pricing. There is a strong market for our trim to B2B customers in Canada, and these sales typically provide strong contribution margins and profitability for our Canadian operators. However, during Q3, we observed what we believe to be a drop level of trim volumes and trim pricing, with spot trim pricing down about 75% year-over-year during the quarter. However, we expect these conditions to begin normalizing in Q4, given the visibility we have from our order book in October, as well as the commencement of some new trim supply agreements with higher contracted pricing, more in line with historical levels, which also began last month. Now, moving on to our international business, which remains a powerful point of distinction for our expanding global platforms. International export sales grew 75% year-over-year to $20.8 million, in line with last quarter's record, as we remain somewhat supply constrained while awaiting more meaningful production increases from the Delta II expansion. We said for the past few quarters that we expected EU GMP-compliant product would be more insulated from price compression, and that we're observing in non-compliant areas of the European supply chain. Our Q3 results continue to prove it with resilient pricing that we've anticipated. Now let me be clear, we have not lowered pricing for our EU GMP compliant product and our pricing outlook remains favorable with demand levels that continue to outpace our current supply capabilities. Our average net selling price in Q3 declined by 9% year over year, but this was entirely driven by a mixed shift to bulk flour and not a reflection of us aggressively lowering prices as some market participants have speculated so far in this earnings season. Now I'd like to discuss the broader regulatory landscape in Europe, which we believe is continuing to move more favorably in our direction. Many market participants have recently described price compression in Germany, particularly for converted product, meaning flour cultivated outside EU GMP conditions and certified later in the supply chain. UK and German regulators, including the Hassen government, are tightening requirements around these conversion pathways. A recent analyst estimates roughly 740 tons of EU GMP certified flour capabilities globally of which only about 57% or roughly 420 tons is EU GMP certified at the source of production. This balance relies on conversion and that's where pricing pressure has been most significant. Village Farms represents a very meaningful percentage of existing compliant at the source EU GMP capacity. As we've stated previously, our Delta production facility is the world's largest single site EU GMP certified cannabis facility, and the vast majority of our production is completed under GMP conditions. Germany alone expects roughly 300 tons of imports this year. and Australia, Israel and the UK import more than 150 tons combined. If GMP washing continues to be curtailed, as we've seen from the UK and Germany regulators, the market for truly at-the-source compliant product could face shortages very quickly. And the market won't just move towards operators with GMP certification. It will move to operators with a consistent flow of quality, certified product at the right price that can consistently deliver. We don't believe anyone is better positioned to benefit from these dynamics than Village Farms. We believe this compliant supply chain organically with the foresight to begin working towards GMP certification nearly six years ago, and we continue to operate this business with industry-leading profitability, which what we feel is one of the most attractive, competitively distinct, and independent growth engines across the global cannabis industry. Now I want to turn to the domestic Canadian business where we're starting to see new opportunities to grow profitable market share as evolving competitive dynamics here are also leaning in our favor. Branded sales were 25.3 million and we continue to hold our top five overall market share position nationally with our brands in the top 10 in every major product category while building this business organically and not through mergers and acquisitions. We continue to make incremental market share gains in vapes and infused pre-rolls during the third quarter, and average net selling prices in the branded channel were up 6% year over year, reflecting our continued focus on higher value products. Non-branded sales of 3.3 million were down from prior year quarter with the variance driven predominantly by the spot market trim dynamics I discussed earlier. Now I'll be candid. Canada is where we built the foundation for our business and our objective remains to grow in line with the market at mid-single digits. We haven't achieved that goal in recent quarters and we're not satisfied with that result. We remain committed to providing our provincial partners, retailers, and consumers consistent supply and service levels and we've been allocating majority of product from the initial harvest from our Delta II expansion to support the domestic Canadian market. From a competitive standpoint, over the course of the past several months, multiple competitors have indicated they are de-emphasizing Canadian branded sales. Some are exiting the dry flower category entirely and one in particular has publicly acknowledged that it can't compete with operators like Village Farms. That means improving competitive dynamics and more room for stronger operators like us with the scale, cost structure, and brands to win long term. We're also encouraged by recent actions by the Canadian government to aggressively combat the illicit market activities in Canada, as well as by last week's news of the move to one federal cannabis excise stamp, which we will anticipate will create additional operating efficiencies for our business. Cannabis is now the number five cash crop nationally in Canada and the number two cash crop in the province of British Columbia. We're very encouraged by the government's increasing favorable view of this important growth driver for the Canadian economy, and this gives us even more confidence to continue investing in our production, our people, and our product portfolio in Canada. Our Delta II expansion remains on track for completion in the first quarter, with expectations to reach its full 40 metric ton annual run rate by the middle of next year. The expansion will support continued organic growth in both the domestic and international export markets through 2028. But as noted in this morning's release, we're already well ahead on planning for the next steps by exercising our conversion rights with Vadextra Holdings for our D1 greenhouse. That's our Delta 1 greenhouse. In mid-October, we notified Vindextra to exercise our contractual right to convert 25% of Delta-1 to cannabis production during 2027, which provides us the optionality to activate an additional 16 acres of 700,000 square feet of production. We have no formal conversion plan today, but giving increasing demand for EU GMP product and improving conditions in the domestic Canadian market We felt it prudent to look at our flexibility to move as quickly as possible if and when that changes. In the Netherlands, Q3 sales were impacted by an increase in plant propagation activities, which supported the wrap-up of our operations at the Phase II facility in Kroningen. This resulted in a sequential decline in sales as compared to the second quarter, but the Kroningen facility is now fully planted which we expect to begin driving stronger revenue growth in the fourth quarter and throughout next year. In September, the Dutch government published its first annual monitoring report conducted by a number of different agencies and coffee shops, growers, municipalities, and regulators all described their experience with the program as positive. Product availability has widened, consumer rate price value more favorable than before the program started, and there was no clear difference in public health, livability, or safety compared to non-participating municipalities. Replacing a tolerated illegal supply chain with a regulated one is not an easy task, but the Dutch government has taken a very thoughtful approach and so forth, showing a lot of signs of success. We believe consumers are developing a preference for the legal supply chain and our team is continuing to work closely with local municipalities and policymakers to help build a model framework all stakeholders can be proud of. We're supportive of revised packaging and labeling requirements to prevent consumers from focusing on high potency products and we're optimistic that recent efforts to formalize administrative processes surrounding the issuance of coffee shop permits may lead to increased store counts in the pilot program in the near-term future. And then finally, in our U.S., our Balance Health Botanical subsidiaries continuing to pursue pathways to participate in the Center for Medicaid and Medicare Innovation pilot program for CBD cannabinoid products. We are awaiting final clarity on the outcome of the pending December 11th federal hemp ban to further assess this opportunity. But we believe BHB is positioned to play a role in this market if federal regulations end up protecting our non-synthetic, full-spectrum products. I'll come back to some closing remarks with our views of the changing regulatory landscape across the US, and in particular, Texas. But now I'd like to hand the call over to Hamid for his review of the financials. Hamid?
Thanks, Mike. And good morning, everyone. All figures I'll reference today are in U.S. dollars unless otherwise noted. Q3 consolidated net sales were $66.9 million, up 5% sequentially and level with Q3 last year, driven by record cannabis sales and continued international growth. Consolidated gross margin was 44% compared to 48% last year and 47% in Q2, with the variance driven by softer spot trim market conditions Mike discussed earlier, offset somewhat but stronger performance in our other segment. SG&A was 24% of sales compared to 23% in Q3 of last year, reflecting higher commercial and marketing spend and the transfer pricing update we discussed last quarter. As a reminder, following the Verdexa transaction last year, more corporate costs are allocated directly to cannabis and I'd also like to point out that SG&A as a percentage of sales improved by 500 basis points sequentially as compared to Q2. Adjusted EBITDA from continuing operations was 18.2 million or 27% of sales compared to our record performance of 20.7 million in Q3 of last year and up 18% sequentially from 15.4 million in Q2. I'd also like to put our year-to-date performance in context. Year-to-date adjusted EBITDA was 43.5 million compared to 41.2 million, which included last year's one-time 4.3 million vendor settlement. Excluding the vendor settlement, year-to-date adjusted EBITDA is up 18%, continuing to outpace revenue growth with a steady pace of improvement we've been delivering throughout 2026. Net income from continuing operations was $10 million or $0.08 per share compared to $10.8 million or $0.09 in Q3 last year and up $7.2 million in Q2. Cash flow from operations was $9.5 million and a quarter. Turning to the cannabis segment. Net sales increased 3% to a record $55 million. International exports increased 75% to 20.8 million, driven by continued strong European demand, and in line with Q2's record performance as we remain somewhat supply constrained while emitting more meaningful contributions from the Delta II expansion. Canadian branded sales were 25.3 million, down 6% year-over-year on lower-value brand volumes, with an average net selling price up 6%. Canadian non-branded sales were 3.3 million compared to 7.3 million last year with the variance driven primarily by lower trim sales. Netherlands sales declined to 2.8 million as a result of the increase in propagation activities which Mike discussed. U.S. cannabis sales from Balanced Health Botanicals were 2.8 million and reflected continued challenges created by unregulated intoxicating hemp products and related state regulatory restrictions. Cannabis gross margin was 48% compared to 55% last year and 51% in Q2, with the year-over-year variance driven primarily by softer trim sales and a more minor impact of the mixed shift of international sales towards bulk flower. Cannabis adjusted EBITDA was $14.7 million or 27% of sales compared to $20.2 million in Q3. Cannabis net income was $7.8 million compared to $12 million last year with the variance driven by lower gross margins and increased operating expenses to support future growth. Cannabis cash flow from operations was $7.3 million compared to $20.6 million with the variance driven by Canadian income tax installments that did not occur last year, some longer payment terms on export sales, and a planned inventory build we feel is important to support an increasingly complex global supply chain. And finally, as we always point out, we incurred Canadian excise taxes of $16.5 million in Q3, or 39% of gross branded sales. In our other segment, which includes clean energy and the remaining produce operations in our Delta 1 greenhouse, we generated net sales of $11.9 million, net income of $2.3 million, and adjusted EBITDA of $3.4 million, with year-over-year improvements driven primarily by stronger yields and pricing. Now turning to the balance sheet. We ended the quarter with approximately $80 million in cash, up $6.3 million sequentially, delivering the stronger second half free cash flows we discussed on last quarter's call. Year-to-date, we generated $35 million from continued operations before working capital adjustments. Working capital adjustments have included approximately $19.7 million of income tax payments, essentially a year and nine months of Canadian income taxes, along with higher receivables and inventory. We invested $17.3 million in CapEx year-to-date, primarily expansion CapEx for Delta II and Gruningen, both of which are now substantially complete. Long-term debt was approximately $39 million at a weighted average rate of 5.7%, and our $10 million revolver is undrawn, and we remain in a strong net cash position of $41 million. Before I hand the call back to Mike, a brief reminder of fourth quarter seasonality in our business. For those of you who are new to our story, there is essentially seasonality in our business related to changes in our growing climate for Delta throughout the year. Contracted produce sales from our Delta One greenhouse to our partner Verdexa Holdings always peak in the second and third quarters. Last year they declined about 60% in Q4 and we would expect a similar trend this year in line with this typical seasonality. Additionally, while our international medical business is still relatively new, last year European order volume slowed significantly over the holiday period in Q4 and resulted in a sequential revenue decline compared to the third quarter. While we haven't observed any material changes in international customer behavior in October, We think it's prudent to remind investors that we may experience similar holiday period seasonality again in 2026. International shipment timing and order sizes can create great quarter-to-quarter variability in our financial performance. So we encourage investors to evaluate the performance of this business over a longer time horizon than one quarter. Back to you, Mike, for closing comments. Thanks, Amit.
You're reading a preview of the VFF Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing